Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07417618 · ClinicalTrials.gov registry record
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
A clinical trial of Type 2 Diabetes and Overweight, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 60,000
- Enrollment target
- 1
- Study location
NCT07417618 is a study of Type 2 Diabetes and Overweight that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 60,000 participants, above the 894-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (6611% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07417618, a study of Type 2 Diabetes and Overweight, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 60,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Sitagliptin
- DRUG Semaglutide
- DRUG Dulaglutide
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60,000 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07417618
The ClinicalTrials.gov registry entry for NCT07417618 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 60,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 894-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (6611% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.
NCT07417618 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07417618 about?
NCT07417618 is a clinical study titled "INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07417618?
This trial is currently active not recruiting. The enrollment target is 60,000 participants. The study started on 2026-01-27. Estimated completion is 2026-03.
What conditions does trial NCT07417618 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Overweight, ASCVD.
What interventions are being tested in trial NCT07417618?
The interventions under investigation include: Tirzepatide (DRUG), Sitagliptin (DRUG), Semaglutide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07417618?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07417618 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.